Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

@article{Keating2005EarlyRO,
  title={Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.},
  author={Michael J. Keating and Susan O'brien and Maher Albitar and Susan Lerner and William Plunkett and Francis J. Giles and Michael Andreeff and Jorge E. Cortes and Stefan H. Faderl and Deborah A. Thomas and Charles A. Koller and William G. Wierda and Michelle A. Detry and Alice Lynn and Hagop M. Kantarjian},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 18},
  pages={
          4079-88
        }
}
  • M. Keating, S. O'brien, H. Kantarjian
  • Published 20 June 2005
  • Medicine, Biology
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Fludarabine and cyclophosphamide (FC), which are active in treatment of chronic lymphocytic leukemia (CLL), are synergistic with the monoclonal antibody rituximab in vitro in lymphoma cell lines. [] Key MethodPATIENTS AND METHODS We conducted a single-arm study of FCR as initial therapy in 224 patients with progressive or advanced CLL. Flow cytometry was used to measure residual disease. Results and safety were compared with a previous regimen using FC.

Figures and Tables from this paper

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
  • K. Foon, M. Boyiadzis, A. Tarhini
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
FCR-Lite is highly effective in previously untreated CLL patients and Grade 3/4 neutropenia was dramatically reduced compared to standard FCR and the data demonstrated FCR- Lite can be safely administered in the community setting.
Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia
TLDR
A modified Fludarabine, Cyclophosphamide and Rituximab protocol is adopted in treating 39 patients with progressive or advanced CLL and concludes that FCR is a feasible, well-tolerated and effective treatment for patients with CLL.
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
TLDR
In a multivariate analysis of patients receiving fludarabine-based therapy at the center, FCR therapy emerged as the strongest independent determinant of survival.
Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication
TLDR
Fludarabine, cyclophosphamide, and mitoxantrone results in a high response rate in previously treated patients with chronic lymphocytic leukemia, indicating that FCM can be an ideal companion for chemoimmunotherapy of patients with CLL.
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
TLDR
In conclusion, CFAR is an active frontline regimen for high-risk CLL and may be a useful frontline regimen to achieve CR in patients with 17p deletion before allogeneic stem cell transplantation.
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia
TLDR
Oral FC and dose-dense rituximab is feasible and active in fit elderly CLL patients, however, myelosuppression is significant and frequent dose adaptations are required implying that these results cannot be generalized to unfit or frail elderly C LL.
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
  • T. Robak, A. Dmoszyńska, S. Moiseev
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
PURPOSE Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered
A prolonged progressive lymphopenia with hypogammaglobulinemia after FCR treatment of chronic lymphocytic leukemia: case report and literature review
TLDR
The present findings suggests that FCR therapy in some indi viduals may lead to the induction of persistent alteration of the cellular and humoral immunity.
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
TLDR
R-FCM is highly effective in previously untreated CLL, with an 82% CR rate and a high proportion of MRD-negative CRs, and warrants further investigation in randomized clinical trials.
Individualized Fludarabine-Based Regimen in Elderly Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
TLDR
The individual regimen of fludarabine combined with rituximab demonstrated marked clinical efficacy and acceptable toxicity in elderly patients with CLL/SLL.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
TLDR
Fludarabine, cyclophosphamide, and filgrastim make up a highly active and well-tolerated regimen in CLL and NHL, and the toxicity of this regimen was mainly hematologic, significant nonhematologic toxicities, including infections, were seen.
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
TLDR
FCM induced a high CR rate, including an important number of MRD(–), in patients with previously treated CLL, and did not hamper stem cell harvesting in patients who were candidates for autologous stem cell transplantation.
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
TLDR
The absence of detectable minimal residual disease by bone marrow biopsy, dual-color flow cytometry, and lg gene rearrangement analysis is achieveable in CLL with fludarabine and is predictive of the response duration.
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
TLDR
Fludarabine and cyclophosphamide seem to have a significant advantage over single-agent fludarABine in the salvage setting, and the CR rate was not increased in previously untreated patients, residual disease detected by flow cytometry was rare and remission durations seemed to be prolonged in this subset of patients.
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.
TLDR
The results suggest that rituximab has clinical activity in pretreated patients with B-CLL and toxicity is tolerable, and other modes of application and the combination with other agents need to be tested.
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease
TLDR
It is confirmed that Fludarabine monotherapy can reduce the neoplastic mass to a subclinical level and the possibility that high dose therapy might produce true complete remission is suggested.
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
TLDR
Fludarabine appears to be an effective initial induction therapy with a reasonable safety profile for patients with CLL.
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
TLDR
Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity and Phase 3 studies using this combination approach for patients with CLL are warranted.
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
TLDR
The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
TLDR
In multivariate analyses controlling for pretreatment characteristics, the patients receiving fludarabine and rituximab had a significantly better progression-free survival (PFS; P < .0001) and overall survival (OS; P = .0006) than patients receivingfludarABine therapy.
...
1
2
3
4
...